By targeting pathophysiological processes within the liver, thyroid hormone receptor beta (THR-β) agonists such as resmetirom are essential for the treatment of metabolic dysfunction associated with hepatic steatosis [15,25,26,27]. Here, THRB is linked to fatty liver disease.